- Original
- Open access
- Published:
Topiramate in the treatment of refractory chronic daily headache. An open trial
The Journal of Headache and Pain volume 6, pages 77–80 (2005)
Abstract
Chronic daily headache (CDH) is a debilitating disorder that becomes a treatment challenge in patients refractory to the treatment. We hereby report our experience with topiramate treatment in patients with refractory CDH. The study design was a prospective, protocol–based follow–up and retrospective analysis of headache diaries. We treated with topiramate at slowly increased moderate increments 11 CDH patients who were refractory to multiple previous treatments. Topiramate treatment was effective in 7 (64%) patients. The treatment resulted in a 66% (median) decrease of the headache days per week and a significant decrease in headache severity, a reduction of the headache hours per day, and weekly analgesic consumption. These effects continued for an average follow–up of 8±4 months. The average effective dose was 100 mg/day. Slowly increasing the drug at moderate increments resulted in high tolerability of topiramate. We found topiramate to be an effective long–standing treatment option for patients with refractory CDH. Slow increments of the dosage contributed to high tolerability of the drug.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Mosek, A., Dano, M. Topiramate in the treatment of refractory chronic daily headache. An open trial. J Headache Pain 6, 77–80 (2005). https://doi.org/10.1007/s10194-005-0155-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10194-005-0155-4